Moreover, drugs currently approved for psoriasis treatment, such as TNF-α antagonists, IL-12/IL-17 inhibitors, and glucocorticoids, exert inhibitory effects on the NF-κB signaling pathway (Vegfors et al., 2012; Uluckan & Wagner, 2016). Here, NFKB1 is linked to psoriasis.